GENNADIL BILITCH: Open Payments
NPI 1164434270 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,912 in 17 payments from 8 companies in 2025. Trend: 2023 $873 · 2024 $1,242 · 2025 $1,912
Food & beverage: $1,912
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $600 |
| Axsome Therapeutics, Inc. | 3 | $374 |
| Otsuka America Pharmaceutical, Inc. | 2 | $270 |
| Alkermes, Inc. | 2 | $256 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 2 | $107 |
| Lundbeck LLC | 2 | $55 |
Products named: VRAYLAR, LYBALVI, Auvelity, REXULTI, FANAPT, IBSRELA, Symbravo, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
